goralatide has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haneda, M; Inomata, N; Kanasaki, K; Kato, Y; Kojima, R; Koya, D; Omata, M; Sho, R; Taniguchi, H | 1 |
| Bignon, J; Briscoe, C; Ilic, V; Lallemand, JY; Liu, JM; Riches, A; Wdzieczak-Bakala, J | 1 |
2 other study(ies) available for goralatide and Disease Exacerbation
| Article | Year |
|---|---|
N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Topics: Analysis of Variance; Animals; Anti-Glomerular Basement Membrane Disease; Biopsy, Needle; Blood Chemical Analysis; Blotting, Western; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrosis; Immunohistochemistry; Injections, Subcutaneous; Kidney Function Tests; Male; Oligopeptides; Probability; Random Allocation; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Statistics, Nonparametric; Transforming Growth Factor beta; Urinalysis | 2006 |
Evidence for an association of high levels of endogenous Acetyl-Ser-Asp-Lys-Pro, a potent mediator of angiogenesis, with acute myeloid leukemia development.
Topics: Animals; Bone Marrow; Disease Progression; Growth Inhibitors; Immunoenzyme Techniques; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred CBA; Neovascularization, Pathologic; Oligopeptides; Spleen | 2006 |